Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06562608
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-16
Brief Title:
Anticholinergic Deprescription in Schizophrenia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Neural Mechanisms of Anticholinergic Burden in Mid- to Late-Life Schizophrenia Spectrum
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this study the investigators will examine whether a deprescription of unnecessary anticholinergic drugs benztropine or trihexyphenidyl can augment quality of life functioning and neurocognition in individuals who with schizophrenia Individuals identified by clinical services who have unneeded prescriptions benztropine or trihexyphenidyl will be eligible for deprescription and study entry Following a baseline evaluation and magnetic resonance imaging MRI participants will will be randomized to either staying on their anticholinergic drugs or undergoing deprescription per routine clinical care and will undergo follow-up evaluations across 6 months The investigators predict that reducing and deprescribing these drug if clinically determined to be unnecessary will will enhance functioning neurocognition
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None